Related references
Note: Only part of the references are listed.Nebulised interferon beta-1a for patients with COVID-19 Comment
Nathan Peiffer-Smadja et al.
LANCET RESPIRATORY MEDICINE (2021)
Type I and III interferon responses in SARS-CoV-2 infection
You-Me Kim et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2021)
Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs
Jonathan Lopez et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics
Nagarjuna R. Cheemarla et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Daniel Blanco-Melo et al.
CELL (2020)
Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19
Annsea Park et al.
CELL HOST & MICROBE (2020)
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
Qian Zhang et al.
SCIENCE (2020)
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Paul Bastard et al.
SCIENCE (2020)
Virology, transmission, and pathogenesis of SARS-CoV-2
Muge Cevik et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Shared and Distinct Functions of Type I and Type III Interferons
Helen M. Lazear et al.
IMMUNITY (2019)
Interferon-λ Mediates Non-redundant Front-Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness
Ioanna E. Galani et al.
IMMUNITY (2017)
Interferon-omega: Current status in clinical applications
Shi-fang Li et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2017)
IKKε and TBK1 are essential components of the IRF3 signaling pathway
KA Fitzgerald et al.
NATURE IMMUNOLOGY (2003)